Skip to main content

Table 7 Overview of most commonly reported AEs

From: Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials

  Carrageenan (n = 126) Placebo (n = 128) Total (n = 254)
  n % n % n %
N. of patients without AEs 103 81,7% 99 77,3% 202 79,5%
Cough 1 0,8% 4 3,1% 5 2,0%
Rhinitis* 0 0,0% 4 3,1% 4 1,6%
Otitis media 3 2,4% 1 0,8% 4 1,6%
Nasal bleeding 3 2,4% 1 0,8% 4 1,6%
Fever, infection NOS** 2 1,6% 2 1,6% 4 1,6%
Bronchitis 2 1,6% 2 1,6% 4 1,6%
Nasal disorders NOS*** 1 0,8% 2 1,6% 3 1,2%
Vomiting 1 0,8% 1 0,8% 2 0,8%
Tonsillitis 2 1,6% 0 0,0% 2 0,8%
Sinusitis 0 0,0% 2 1,6% 2 0,8%
Rash 0 0,0% 2 1,6% 2 0,8%
Nausea 0 0,0% 2 1,6% 2 0,8%
Ear pain 1 0,8% 1 0,8% 2 0,8%
Conjunctivitis 1 0,8% 1 0,8% 2 0,8%
Adenoids 1 0,8% 1 0,8% 2 0,8%
Abdominal pain 1 0,8% 1 0,8% 2 0,8%
  1. *Difference between groups statistically significant, p = 0.045.
  2. **Including pyrexia, febrile infection and viral infection (not specified).
  3. ***Including nasal itching, feeling of burning in the nose and smell disturbance.
  4. NOS = not specified.